Drugs Containing Excipient (Inactive Ingredient) POLOXAMER 331

Generic drugs containing POLOXAMER 331 excipient

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	mefloquine hydrochloride	0054-0025	POLOXAMER 331

POLOXAMER 331: Patent Landscape and Market Trajectory Analysis

Last updated: February 19, 2026

Poloxamer 331, a nonionic triblock copolymer, presents a complex patent landscape with significant implications for market growth. Its primary role as a pharmaceutical excipient, particularly in drug delivery systems and formulations, underpins its commercial value. Analysis of recent patent filings reveals a focus on novel applications, improved manufacturing processes, and enhanced drug release profiles. The financial trajectory of Poloxamer 331 is directly correlated with the innovation pipeline of pharmaceutical companies utilizing this excipient.

What is the patent landscape for Poloxamer 331?

The patent landscape for Poloxamer 331 is characterized by a gradual increase in filings over the past decade, with a notable surge in the last three to five years. These patents primarily fall into categories related to its use in specific drug formulations, modifications to the polymer for enhanced properties, and novel methods of synthesis.

Key Patent Categories

• Formulation Patents: These patents claim the use of Poloxamer 331 in combination with specific active pharmaceutical ingredients (APIs) to achieve desired drug delivery characteristics. This includes patents for sustained-release formulations, targeted delivery systems (e.g., for ophthalmic or parenteral administration), and solubility enhancement of poorly soluble drugs.
• Modification Patents: Research is ongoing to modify the structure of Poloxamer 331 to alter its physical and chemical properties. Patents in this area focus on variations in molecular weight, hydrophile-lipophile balance (HLB), and the introduction of functional groups to improve biocompatibility, stability, or interaction with specific APIs.
• Synthesis and Manufacturing Patents: While the basic synthesis of poloxamers is established, patents continue to emerge that describe improved or more efficient manufacturing processes. These can lead to higher purity grades, reduced production costs, or the ability to create specific molecular architectures relevant to advanced pharmaceutical applications.
• Combination Therapy Patents: Some patents explore the co-formulation of multiple APIs with Poloxamer 331, creating combination drug products with synergistic therapeutic effects or simplified dosing regimens.

Geographic Distribution of Patents

The majority of Poloxamer 331-related patent activity originates from North America (United States) and Europe, reflecting the significant pharmaceutical R&D hubs in these regions. Asia, particularly China and Japan, is also showing increasing patent filings, indicating growing investment in pharmaceutical excipient innovation.

Notable Patent Filings and Trends

Recent patent filings highlight several key trends:

• Therapeutic Area Expansion: While Poloxamer 331 has a long history in various pharmaceutical applications, new patents are emerging for its use in niche and high-growth therapeutic areas such as oncology, neurology, and rare diseases.
• Combination Products: There is a clear trend towards patents that protect not just the excipient itself, but its specific application within a complex drug product designed to address unmet medical needs.
• Advanced Drug Delivery: Patents are increasingly focused on utilizing Poloxamer 331 in sophisticated drug delivery systems, including nanoparticles, micelles, and hydrogels, for improved efficacy and reduced side effects.

What is the current market size and projected growth for Poloxamer 331?

The market for Poloxamer 331 is substantial and expected to grow, driven by the expanding pharmaceutical industry and the increasing demand for advanced drug delivery solutions. Quantifying the precise market size for a specific excipient like Poloxamer 331 can be challenging due to proprietary data and the commoditized nature of some excipient categories. However, industry reports and market analysis provide a strong indication of its trajectory.

Estimated Market Size and Growth Rate

Industry estimates place the global pharmaceutical excipients market in the tens of billions of dollars annually, with a projected compound annual growth rate (CAGR) of 5-7%. Poloxamers, as a class, represent a significant segment within this market due to their versatility. While specific figures for Poloxamer 331 are not always disaggregated, it is understood to contribute meaningfully to this growth.

• Projected CAGR: Analysts project the Poloxamer market segment to grow at a CAGR of approximately 5.5% to 6.5% over the next five to seven years.
• Market Drivers: Key drivers include:
  • Increasing prevalence of chronic diseases requiring long-term medication.
  • Growing demand for oral solid dosage forms and advanced drug delivery systems.
  • Expansion of the biopharmaceutical sector, which often requires specialized excipients for protein and peptide stabilization and delivery.
  • Technological advancements in drug formulation.

Factors Influencing Market Growth

• Drug Development Pipeline: The number of new drug approvals that utilize Poloxamer 331 in their formulations is a direct indicator of market demand.
• Regulatory Landscape: Stringent quality and purity requirements for pharmaceutical excipients can impact market entry and production costs.
• Competition: The availability of alternative excipients with similar functionalities presents a competitive challenge.
• Cost-Effectiveness: The balance between the performance benefits of Poloxamer 331 and its cost relative to alternatives is a critical factor for manufacturers.

Geographic Market Distribution

The demand for Poloxamer 331 mirrors the global pharmaceutical market. North America and Europe currently represent the largest markets due to the established pharmaceutical industries and extensive R&D activities. The Asia-Pacific region is anticipated to exhibit the highest growth rate, driven by rising healthcare expenditures, increasing generic drug production, and expanding pharmaceutical manufacturing capabilities in countries like China and India.

What are the primary applications of Poloxamer 331 in the pharmaceutical industry?

Poloxamer 331's versatility as a pharmaceutical excipient stems from its unique amphiphilic properties, allowing it to act as a solubilizer, emulsifier, surfactant, and stabilizer across a wide range of pharmaceutical formulations.

Key Pharmaceutical Applications

• Solubilization of Poorly Soluble Drugs: Many new chemical entities (NCEs) suffer from poor aqueous solubility, limiting their oral bioavailability. Poloxamer 331 can form micelles in aqueous solutions, encapsulating hydrophobic drug molecules within the micellar core and thereby increasing their apparent solubility. This is crucial for oral dosage forms, injectables, and ophthalmic solutions.
• Emulsification: Poloxamer 331 stabilizes oil-in-water and water-in-oil emulsions, which are common in topical creams, lotions, and some oral suspensions. Its surfactant properties reduce interfacial tension between immiscible phases, preventing phase separation.
• Drug Delivery Systems:
  • Sustained and Controlled Release: Poloxamer 331 can be incorporated into matrix systems or gels to control the rate of drug release. Its thermorelain properties, where it transitions from a liquid to a gel at body temperature, are particularly useful for injectable depot formulations that provide prolonged drug delivery.
  • Nasal and Ophthalmic Delivery: Its low toxicity and ability to enhance drug penetration make it suitable for non-oral routes of administration.
  • Solubilizing Excipient in Injectables: For intravenous and intramuscular drug formulations, Poloxamer 331 improves the solubility of poorly water-soluble APIs, enabling higher drug concentrations in smaller volumes.
• Wetting Agent: In solid dosage forms like tablets, Poloxamer 331 can improve the wetting of hydrophobic drug particles, facilitating disintegration and dissolution.
• Stabilizer: It can help stabilize suspensions and emulsions against aggregation and sedimentation.
• Pre-formulation Studies: Due to its ability to solubilize and compatibilize a wide range of compounds, Poloxamer 331 is often used in early-stage drug development to assess the potential for formulating challenging APIs.

Specific Examples of Use

• Ophthalmic Solutions: Commonly used to improve the solubility and ocular penetration of antiglaucoma drugs and antibiotics.
• Injectable Formulations: Employed in depot injections for chronic conditions like hormone replacement therapy or treatment of certain cancers.
• Oral Drug Products: Utilized in soft gelatin capsules and solid dispersions to enhance the bioavailability of poorly soluble oral medications.
• Topical Formulations: Acts as an emulsifier and solubilizer in creams and ointments for dermatological applications.

What are the financial implications of Poloxamer 331's patent expiry?

The expiry of key patents related to Poloxamer 331 and its specific applications has significant financial implications, primarily benefiting generic manufacturers and potentially leading to price erosion for branded formulations.

Impact of Patent Expiry

• Increased Generic Competition: As patents expire, generic drug manufacturers can enter the market with bioequivalent versions of drugs that utilize Poloxamer 331. This leads to increased competition, often resulting in lower prices for these medications.
• Price Erosion: The influx of generic alternatives typically drives down the price of the original branded drug. This directly impacts the revenue streams of the innovator company.
• Opportunity for Excipient Manufacturers: While patent expiry of end-user drug products can decrease demand for specific branded formulations, it can increase overall demand for the excipient itself as generic manufacturers ramp up production. Manufacturers of Poloxamer 331 may see an increase in volume demand from generic drug producers.
• Shift in R&D Focus: For innovator companies, the expiry of a patent signals a need to shift R&D focus towards new drug candidates or next-generation formulations. This could involve developing novel formulations of existing drugs that incorporate improved excipients or entirely new drug entities.
• Strategic Opportunities for Excipient Suppliers: Suppliers of Poloxamer 331 can leverage patent expiries by offering high-quality, cost-competitive grades to generic manufacturers. Furthermore, they may focus on developing novel, patentable modifications or grades of Poloxamer 331 for use in next-generation drug formulations by innovator companies.

Timeline of Patent Expiries

The timeline for patent expiries is critical. Patents for specific drug formulations containing Poloxamer 331 will expire at different times depending on the original drug approval date and patent term extensions. It is essential to track individual drug patents that list Poloxamer 331 as a key component.

• Generic Entry: Following patent expiry, there is often a lag of 12-24 months before generic versions are available in the market due to the time required for regulatory approval and manufacturing scale-up.
• Market Dynamics: The financial impact is not solely about price reduction but also market share dynamics. Generic drugs often capture a significant portion of the market rapidly after their introduction.

Financial Projections

• Revenue Decline for Innovators: Companies relying on revenue from products with expiring Poloxamer 331 patents can expect a significant decline in sales for those specific products.
• Increased Volume for Excipient Suppliers: Conversely, suppliers of Poloxamer 331 may experience an increase in overall sales volume as generic drug production scales up. However, pricing pressure on the excipient itself may also occur if supply outstrips demand or if alternative excipients become more cost-effective.
• Investment in New Patents: Pharmaceutical companies will intensify efforts to secure new intellectual property around novel formulations and applications to maintain market exclusivity and profitability.

What are the key manufacturing considerations and quality standards for Poloxamer 331?

The manufacturing of Poloxamer 331 for pharmaceutical use is governed by stringent quality standards to ensure patient safety and therapeutic efficacy. Deviations in manufacturing processes or impurity profiles can have significant consequences for drug product performance and regulatory approval.

Manufacturing Process

Poloxamer 331 is produced through a controlled polymerization process involving ethylene oxide and propylene oxide. The synthesis occurs via anionic ring-opening polymerization, where ethylene oxide and propylene oxide are sequentially added to an initiator, typically a diol or triol. The resulting polymer has a central hydrophobic polypropylene oxide (PPO) block and two flanking hydrophilic polyethylene oxide (PEO) blocks.

• Control of Molecular Weight and Purity: Precise control over the molar ratios of ethylene oxide and propylene oxide, as well as reaction conditions (temperature, pressure, catalyst concentration), is critical to achieve the desired molecular weight distribution and HLB value characteristic of Poloxamer 331.
• Removal of Byproducts: Residual monomers (ethylene oxide, propylene oxide) and potential byproducts such as cyclic ethers and aldehydes must be minimized to meet pharmaceutical specifications.
• Batch-to-Batch Consistency: Reproducibility in manufacturing is paramount to ensure consistent product performance in drug formulations.

Key Quality Standards and Regulatory Requirements

Pharmaceutical-grade Poloxamer 331 must comply with pharmacopoeial monographs and regulatory guidelines.

• Pharmacopoeial Standards: Poloxamer 331 is listed in major pharmacopoeias, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define specific tests and acceptance criteria for:
  • Identification: Spectroscopic methods (e.g., IR spectroscopy) and chemical tests to confirm the polymer structure.
  • Assay: Determination of the polymer content.
  • Molecular Weight: Methods like gel permeation chromatography (GPC) or viscosity measurements to confirm the average molecular weight.
  • Hydrophile-Lipophile Balance (HLB): Determination of the emulsification properties.
  • Impurities: Limits for residual ethylene oxide, propylene oxide, and other potentially toxic byproducts (e.g., 1,4-dioxane).
  • pH, Turbidity, and Clarity: For solutions.
  • Heavy Metals: Limits for trace metal contamination.
• Good Manufacturing Practices (GMP): Manufacturing facilities must adhere to GMP guidelines to ensure product quality, safety, and traceability. This includes robust quality control systems, validated processes, and proper documentation.
• ICH Guidelines: International Council for Harmonisation (ICH) guidelines, such as ICH Q3A/B (Impurities) and ICH Q7 (GMP for Active Pharmaceutical Ingredients), are applicable and guide the control of impurities and overall quality management.
• Supplier Qualification: Pharmaceutical companies rigorously qualify their excipient suppliers, conducting audits of manufacturing sites and reviewing quality agreements to ensure compliance with regulatory requirements.

Challenges in Manufacturing and Quality Control

• Control of Residual Monomers: Ethylene oxide and propylene oxide are volatile and toxic, requiring specialized handling and stringent process controls to ensure their levels are below pharmacopoeial limits.
• Batch Variability: Subtle variations in polymerization conditions can lead to differences in molecular weight distribution or impurity profiles, which can affect formulation performance.
• Trace Impurities: Detecting and quantifying trace impurities at very low levels (e.g., parts per million) requires sensitive analytical techniques and expertise.
• Supply Chain Security: Ensuring a consistent and reliable supply of high-quality Poloxamer 331 from qualified manufacturers is critical for uninterrupted drug production.

What are the competitive dynamics and key players in the Poloxamer 331 market?

The market for Poloxamer 331 is characterized by a limited number of major manufacturers who supply pharmaceutical-grade material, alongside a broader landscape of companies utilizing it in various drug formulations.

Major Manufacturers and Suppliers

The production of pharmaceutical-grade poloxamers, including Poloxamer 331, is highly specialized. Key global players dominate this segment due to the technical expertise and capital investment required for compliant manufacturing.

• BASF: A leading global producer of chemicals and materials, BASF offers a wide range of poloxamers under its Kolliphor® (formerly Pluronic®) brand. They are a significant supplier of Poloxamer 331 for pharmaceutical applications.
• Dow Chemical Company: Another major chemical conglomerate, Dow also produces poloxamers, historically under the Pluronic® brand (now part of BASF's portfolio for this specific product line), and continues to be a key player.
• SABO S.p.A.: This Italian company is a significant manufacturer of excipients, including poloxamers, often serving the European and global markets.
• Other Regional Manufacturers: Depending on the region, smaller or more specialized manufacturers may also supply pharmaceutical-grade poloxamers. However, global pharmaceutical companies often prefer to source from large, established players with a proven track record of quality and regulatory compliance.

Competitive Landscape for Formulators

The competitive dynamics shift when considering companies that use Poloxamer 331 in their drug products.

• Innovator Pharmaceutical Companies: These companies develop novel drugs and proprietary formulations utilizing Poloxamer 331. Their competitive advantage lies in their R&D, clinical trials, and patent protection. Examples include companies developing new injectable or ophthalmic therapies.
• Generic Pharmaceutical Companies: Following patent expiry, generic manufacturers compete on price and market access. Their success depends on efficient manufacturing of bioequivalent products using cost-effective sources of Poloxamer 331.
• Contract Development and Manufacturing Organizations (CDMOs): CDMOs play a crucial role by offering formulation development and manufacturing services to both innovator and generic companies. They often have expertise in utilizing various excipients, including Poloxamer 331, for diverse drug delivery systems.
• Specialty Pharmaceutical Companies: Companies focusing on specific therapeutic areas or drug delivery technologies may also be key users, innovating with Poloxamer 331 for specialized applications like advanced nanoparticle or hydrogel systems.

Strategic Considerations for Market Players

• For Excipient Manufacturers:
  • Quality and Regulatory Compliance: Maintaining the highest standards of GMP and pharmacopoeial compliance is non-negotiable.
  • Innovation: Developing new grades of Poloxamer 331 with enhanced properties or improved impurity profiles can create competitive differentiation.
  • Supply Chain Reliability: Ensuring consistent supply and robust logistics is critical for maintaining customer loyalty.
  • Cost Management: Optimizing manufacturing processes to offer competitive pricing, especially for the generic market.
• For Pharmaceutical Formulators:
  • Excipient Sourcing: Strategic selection of excipient suppliers based on quality, price, reliability, and regulatory support.
  • Formulation Expertise: Developing robust and patentable formulations that leverage the unique properties of Poloxamer 331.
  • Intellectual Property: Securing strong patent protection for novel drug products and formulations.
  • Market Access and Reimbursement: Navigating regulatory pathways and securing favorable pricing and reimbursement for finished drug products.

Key Takeaways

• Patent Landscape: The patent landscape for Poloxamer 331 is active, with ongoing filings focused on novel formulations, modifications, and manufacturing processes, particularly in advanced drug delivery systems and niche therapeutic areas.
• Market Growth: The Poloxamer 331 market is poised for steady growth, driven by the expanding pharmaceutical industry, increasing demand for advanced drug delivery solutions, and growth in emerging markets.
• Diverse Applications: Poloxamer 331 is a critical excipient for solubilizing poorly soluble drugs, stabilizing emulsions, and enabling sustained/controlled release formulations across oral, parenteral, and topical drug products.
• Patent Expiry Impact: Patent expiries for drug products utilizing Poloxamer 331 will intensify generic competition, leading to price erosion for branded products and increased demand for the excipient from generic manufacturers.
• Manufacturing Rigor: Pharmaceutical-grade Poloxamer 331 production requires strict adherence to GMP and pharmacopoeial standards to control molecular weight, purity, and minimize residual monomers, ensuring patient safety and efficacy.
• Competitive Players: The market is dominated by a few large chemical manufacturers for the excipient itself, while the user base comprises a diverse range of innovator, generic, and specialty pharmaceutical companies, as well as CDMOs.

Frequently Asked Questions

1. What is the primary regulatory concern regarding Poloxamer 331 impurity profiles? Residual levels of ethylene oxide and propylene oxide monomers are the primary regulatory concern due to their potential toxicity.
2. How does Poloxamer 331's thermoreversible gelation property benefit pharmaceutical formulations? This property allows for the development of injectable depot formulations that transition from a liquid state at room temperature to a gel at body temperature, enabling prolonged and controlled drug release at the injection site.
3. What is the typical range for the Hydrophile-Lipophile Balance (HLB) of Poloxamer 331? Poloxamer 331 typically has an HLB value in the range of 15-20, indicating its strong hydrophilic character and suitability for creating stable oil-in-water emulsions.
4. How does the increasing focus on biopharmaceuticals impact the demand for Poloxamer 331? The growth in biopharmaceuticals, such as proteins and peptides, which often have solubility and stability challenges, increases the demand for excipients like Poloxamer 331 that can aid in their formulation and delivery.
5. What are the key analytical techniques used to characterize Poloxamer 331 and its impurities? Key techniques include Infrared (IR) spectroscopy for identification, Gel Permeation Chromatography (GPC) for molecular weight distribution, Gas Chromatography (GC) for residual monomers, and High-Performance Liquid Chromatography (HPLC) for related substances.

---

Citations

[1] U.S. Pharmacopeia. (n.d.). Poloxamer. Retrieved from [USP-NF Monograph Database] (Note: Specific monograph access requires subscription). [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Poloxamer. Retrieved from [Ph. Eur. Monograph Database] (Note: Specific monograph access requires subscription). [3] Grand View Research. (2023). Pharmaceutical Excipients Market Size, Share & Trends Analysis Report By Product (Polymers, Pharma Lipids, etc.), By Application (Oral, Injectable, etc.), By Region, And Segment Forecasts, 2023 - 2030. [4] Mordor Intelligence. (2023). Pharmaceutical Excipients Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). [5] BASF SE. (n.d.). Kolliphor® Poloxamers. Retrieved from [BASF Website Product Information] [6] Dow Chemical Company. (n.d.). Pluronic® block copolymers. Retrieved from [Dow Website Product Information] (Historical context for Poloxamer 331's origin).